Group 1 - The core viewpoint of the article highlights that Yidu Technology (02158) has demonstrated confidence in its intrinsic value through a series of share buybacks, totaling nearly 68 million HKD since the start of 2026's first buyback on January 26, completing 16 buybacks in less than a month [1][1][1] - The company repurchased 163,000 shares at approximately 6 HKD per share on February 20, costing over 970,000 HKD, marking its first buyback operation after the Spring Festival [1][1][1] Group 2 - The AI healthcare industry is currently experiencing a golden period of development, driven by both policy and market forces, with a comprehensive acceleration in commercialization [1][1][1] - The Chinese government has issued implementation opinions for the application development of "Artificial Intelligence + Healthcare," aiming to establish a number of clinical vertical large models by 2027 and achieve intelligent auxiliary diagnosis coverage in secondary hospitals by 2030 [1][1][1] - The market for AI healthcare in China is projected to grow from 8.8 billion CNY in 2023 to 315.7 billion CNY by 2033, with a compound annual growth rate of 43.1% according to Frost & Sullivan [1][1][1]